Brian V. Elliott Joins Arev Life Sciences Global Corporation

VANCOUVER, BC / TheNewswire / Apr 19, 2022 / AREV Life Sciences Global Corp. (CSE:AREV) (OTC:AREVF) (“AREV” or the “Company”) AREV Life Sciences Global Corporation today announced the appointment of Brian V. Elliott, B Comm to its Board of Directors.

In pursuit of innovative global health solutions, AREV Life Sciences Global Corporation adds Brian V. Elliott to its Board of Directors.

Brian V. Elliott is an international strategist and leader with more than 35 years of senior management positions in the pharmaceutical and health-related public sectors. He spent 10 years with the Irish Government Industrial Development Authority in Ireland, France and Lesotho.

Brian entered the pharmaceutical industry and held the position of International Sales Director at Norton Healthcare Generics, based in Ireland and the UK, where he led their Ireland-based manufacturing operations. He assumed the position of Director of Janssen Pharmaceutica NV with responsibility for China, and was subsequently appointed International Trade Director, Janssen Africa, Middle East, West Asia.

He was recruited by the Belgian biotech company Tibotec-Virco NV, as Senior Vice President, Corporate Alliances and Business Development. Brian was also CEO of Tibotec Virco, Ireland.

Brian V. Elliott founded Axios International Consultants Ltd in Ireland and chaired the organization for 5 years, during which time he carried out many health-related projects in developing countries, including:

Negotiator of the United Nations Program for HIV/AIDS (UNAIDS) with the pharmaceutical industry on access to antiretrovirals, co-designing the UNAIDS Drug Access Initiative and piloting projects in Vietnam, Chile, Uganda and Côte d’Ivoire.

Advisor to the Danish Ministry of Foreign Aid for international HIV/AIDS policy.

The design and implementation of several global access initiatives, including:

Bristol Myers Squibb – Secure the Future project in South Africa,

Abbott – Step Forward for Children project in Tanzania and Burkina Faso, Abbott

Gilead – Worldwide Viread Donation Program

Pfizer – diflucan donation project Pfizer

Roche-Blue Skies project in southern Africa

Glaxo Wellcome-tiered pricing for developing countries.

In 2008, Brian was appointed Executive Director of The Medical Transparency Alliance (MeTA), an alliance of the Department for International Development- UK, World Bank and World Health Organization (WHO) aimed at increasing access to essential medicines in 7 pilot countries (Peru, Jordan, Kyrgyzstan, Uganda, Zambia, Ghana and the Philippines). He was also a member of the Affordable Medicine Facility for Malaria (AMFm) Expert Advisory Panel on Project Evaluation Process Review.

Recently, Brian has advised a number of major pharmaceutical companies developing programs to provide global access to medicines, working closely with Johnson & Johnson Global Public Health Group and other multinational companies. These efforts include reporting to companies, agencies and foundations on critical aspects of HIV/AIDS treatment in developing countries.

Projects in these areas include: Working closely with Indian antiretroviral drug manufacturers to advocate with Global Fund and PEPFAR to adapt their procurement processes, reporting. for the United Nations Industrial Development Organization (UNIDO), UNAIDS and the WHO on the security of supply of HIV/AIDS products, the review of the WHO’s Appropriate Use Criteria (AUC)/UNIDO Pharmaceutical Manufacturing Plan for Africa, and the providing strategies for the implementation of the pharmaceutical production plan for Africa for WHO/UNIDO.

Brian continues to advise Johnson & Johnson Global Public Health Group and several other international pharmaceutical companies on establishing Global Access to Medicine programs in developing countries. He drafted the WHO Procurement and Supply Management (PSM) Profile Update, which updated PSM profiles for 85 countries, allowing assessment of the implementation status of CD4 and VL technology.

Addressing the UN Special Assembly on the looming crisis in HIV treatment, he formed and advised a coalition of 11 Indian generic pharmaceutical manufacturers and led discussions between them, the President’s Emergency Plan for AIDS Relief (PEPFAR) and The Global Fund to address the issues. perceived inequalities in the purchasing system for antiretrovirals in low- and middle-income countries, market dynamics and the risk of security of supply.

He is currently leading the establishment of clinical trials of 2 new drugs to treat NCDs and 2 Covid vaccine candidates in Kenya and advising governments in sub-Saharan Africa.

Furthermore, the company is pleased to announce that the company has issued 150,000 stock options to directors, officers and advisers of the company at a price of $0.22 for a period of 5 years from the date of issue. These options immediately vest.

For more information, please contact Mike Withrow, arevlifesciences@gmail.com 778-929-6536. For more information, visit www.arevlifesciences.com.

On behalf of the Board,

Mike Withrow
CEO & director

ABOUT AREV Life Sciences Global Corp.

AREV Life Sciences Global Corp. is a fully integrated, publicly traded, life sciences start-up company committed to delivering therapeutic interventions to public health through unique compound extraction, discovery, innovation and successful collaborations. The company’s leadership is driving discovery programs for clinical complexities caused by malnutrition, viral infectious diseases and the inflammatory response system. AREV invests in commercial innovations in phytomedicinal discoveries of small molecule antivirals and related neglected chronic comorbidities and innovations in human nutrition. AREV is committed to designing and delivering innovation in rational drug design, driven by presenting global epidemiological features of multiple challenges to international human and animal health. AREV is a member of both BIOTECanada and the Biotechnology Innovation Organization (BIO).

NEITHER THE CANADIAN SECURITIONS EXCHANGE NOR ITS REGULATORY SERVICE PROVIDER HAVE REVIEWED OR ACCEPTED RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

FORWARD-LOOKING INFORMATION

Neither the Canadian Securities Exchange nor its Regulatory Services Provider (as that term is defined in the CSE’s policies) assumes any responsibility for the suitability or accuracy of this release. This press release may contain forward-looking statements that are subject to risks and uncertainties. All statements contained within, other than statements of historical fact, should be considered forward-looking. While the Company believes that the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments could differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include market prices, exploitation and exploration success, and continued availability of capital and financing, and general economic, market or business conditions. There can be no assurance that such statements will prove correct and, therefore, readers are advised to rely on their own assessment of such uncertainties. We assume no obligation to update any forward-looking statements, except as required under applicable law. This press release contains forward-looking statements. The use of any of the words “anticipate”, “continue”, “estimate”, “expect”, “may”, “will”, “project”, “would”, “believe” and similar expressions are intended to indicate future – looking statements. While the company believes that the expectations and assumptions on which the forward-looking statements are based are reasonable, no undue reliance should be placed on the forward-looking statements because the company makes no representation that they will prove correct. Because forward-looking statements relate to future events and conditions, they by their nature involve risks and uncertainties. These statements speak only as of the date of this press release. Actual results may differ materially from currently expected results due to a number of factors and risks, various risk factors discussed in the business.s Management discussion and analysis under the company profile at: www.sedar.com.

Copyright (c) 2022 TheNewswire – All rights reserved.

The preceding article is from one of our external contributors. It does not represent Benzinga’s opinion and has not been edited.


This post Brian V. Elliott Joins Arev Life Sciences Global Corporation was original published at “https://www.benzinga.com/22/04/26777436/brian-v-elliott-joins-arev-life-sciences-global-corporation”

Leave a Reply

Your email address will not be published.